GlassScriptPhysician profile
Ashley Stroud
NPI 1457845240
$6,694.66
in general payments reported to CMS, 2019-2025
29 companies · $1,646 in 2025
The $1,646 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,265 · 2022: $1,443 · 2023: $968 · 2024: $1,373 · 2025: $1,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,887 · Education: $99.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,887.06 |
| Education | $99.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,899.55 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $627.47 | 2021-2025 | Trelegy Ellipta, Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $485.10 | 2021-2025 | Takhzyro, Hyqvia, Cuvitru |
| Genzyme Corporation | $478.14 | 2021-2025 | |
| Csl Behring | $417.43 | 2021-2025 | Andembry, Haegarda, Hizentra |
| Biocryst US Sales Co., LLC | $375.13 | 2023-2025 | Orladeyo |
| Regeneron Healthcare Solutions, INC. | $367.62 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $330.63 | 2021-2025 | |
| Blueprint Medicines Corporation | $296.61 | 2023-2025 | Ayvakit |
| Lilly USA, LLC | $202.97 | 2024-2025 | Ebglyss |
| Grifols USA, LLC | $147.94 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Pfizer INC. | $135.13 | 2021-2025 | |
| Ars Pharmaceuticals Operations, INC. | $120.29 | 2025 | Neffy |
| Horizon Therapeutics Plc | $95.03 | 2021-2022 | |
| Genentech USA, INC. | $89.90 | 2021-2024 | Xolair |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $68.44 | 2021-2023 | |
| Acadia Pharmaceuticals INC | $66.33 | 2024 | Daybue |
| Adma Biomanufacturing LLC | $61.81 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.47 | 2021-2023 | Spiriva Respimat |
| Pharming Healthcare, INC. | $56.12 | 2021-2025 | Ruconest |
| Octapharma USA, INC. | $45.62 | 2021 | |
| Incyte Corporation | $44.72 | 2024 | Opzelura |
| Ionis Pharmaceuticals, INC. | $44.25 | 2025 | Dawnzera |
| Amgen INC. | $40.11 | 2023-2024 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $36.84 | 2022 | |
| Cycle Pharmaceuticals INC | $35.59 | 2024-2025 | Sajazir |
| Alk-Abello, INC | $31.80 | 2021 | |
| Organon LLC | $18.74 | 2025 | Vtama |
| Greer Laboratories, INC. | $16.88 | 2023 | Palforzia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Stroud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.